AbCellera Biologics Inc.
ABCLNASDAQHealthcare● Active
$5.61
$-0.01(-0.22%)
Market Cap$1.7B
P/E Ratio—
52W High$6.79
52W Low$2.33
AbCellera Biologics Inc. (ABCL) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ABCL · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $75.13M | $28.83M | $38.02M | $485.42M | $375.20M |
| Cost of Revenue | $28.82M | $0.00M | $0.00M | $66.44M | $45.52M |
| Gross Profit | $46.31M | $28.83M | $38.02M | $418.99M | $329.69M |
| Gross Margin %(computed) | 61.64% | 100.00% | 100.00% | 86.31% | 87.87% |
| Operating Expenses | |||||
| R&D Expenses | $186.83M | $167.26M | $175.66M | $107.88M | $62.06M |
| G&A Expenses | $0.00M | $72.71M | $61.00M | $55.48M | $41.85M |
| Total Operating Expenses | $263.41M | $343.60M | $275.23M | $202.48M | $125.27M |
| Operating Income | ($217.10M) | ($314.77M) | ($237.21M) | $216.51M | $204.41M |
| Operating Margin %(computed) | -288.98% | — | -623.82% | 44.60% | 54.48% |
| Interest Income | $28.33M | $38.47M | $42.25M | $16.08M | $3.33M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $4.04M | $5.22M |
| Income Before Tax | ($177.59M) | ($200.40M) | ($174.03M) | $239.10M | $219.15M |
| Income Tax Expense | ($31.18M) | ($37.54M) | ($27.63M) | $80.58M | $65.69M |
| Net Income | ($146.41M) | ($162.86M) | ($146.40M) | $158.52M | $153.46M |
| Net Margin %(computed) | -194.88% | -564.83% | -385.00% | 32.66% | 40.90% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.49 | $-0.55 | $-0.51 | $0.56 | $0.56 |
| Wtd Avg Shares | 298.71M | 294.33M | 289.17M | 285.06M | 275.76M |
| EBITDA | ($188.28M) | ($204.15M) | ($192.16M) | $260.17M | $239.15M |
| EBITDA Margin %(computed) | -250.61% | -708.04% | -505.35% | 53.60% | 63.74% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more AbCellera Biologics Inc. data
About AbCellera Biologics Inc. (ABCL) Income Statement
AbCellera Biologics Inc. (ABCL) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ABCL reported revenue of $0.08B, gross profit of $0.05B (gross margin 61.64%), and net income of ($0.15B) — a net profit margin of -194.88%.
Frequently asked questions
ABCL · 4 questionsAbCellera Biologics Inc. (ABCL) reported revenue of $0.08B for 2025, up 160.6% year-over-year.
ABCL revenueABCL salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08